Sugi Predict

Sugi Predict / Compounds / SCHEMBL2937893

SCHEMBL2937893

SCHEMBL2937893

CC1C(=O)N(c2ccc(S(=O)(=O)C(F)(F)F)cc2)C(=O)N1Cc1ccncc1NC(N)=O

nearest known ligand 0.62

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 2/20 0.62
▸ KIF11 P52732 1/20 0.37
▸ SMO Q99835 4/20 0.37
▸ NAMPT P43490 1/20 0.35
▸ RXFP1 Q9HBX9 2/20 0.34
▸ CCNE2 O96020 1/20 0.32
▸ CCNE1 P24864 1/20 0.32
▸ CDK2 P24941 1/20 0.32
▸ GSK3B P49841 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ CTSS P25774 1/20 0.32
▸ CHRM4 P08173 1/20 0.31
▸ PTGS1 P23219 1/20 0.31
▸ PTGS2 P35354 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2939954 0.92 IGF1R (0.60) IGF1RSMONAMPTRXFP1CCNE2
SCHEMBL2941779 0.90 IGF1R (0.61) IGF1RSMONAMPTRXFP1TP53
SCHEMBL2941577 0.89 IGF1R (0.60) IGF1RSMONAMPTRXFP1TP53
SCHEMBL2940490 0.89 IGF1R (0.61) IGF1RSMONAMPTRXFP1TP53
SCHEMBL2937967 0.88 IGF1R (0.56) IGF1RSMONAMPTRXFP1TP53
SCHEMBL2941498 0.88 IGF1R (0.64) IGF1RSMONAMPTCTSSPTGS1
SCHEMBL2941137 0.88 IGF1R (0.58) IGF1RSMONAMPTRXFP1TP53
SCHEMBL2939014 0.88 IGF1R (0.61) IGF1RSMONAMPTCTSSPTGS1
SCHEMBL2938404 0.88 IGF1R (0.55) IGF1RRXFP1TP53
SCHEMBL2939078 0.88 IGF1R (0.55) IGF1RSMONAMPTRXFP1CCNE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 — — US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 — — EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 — — US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 — — US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 IGF1R 1595/4885KIF11 2253/4885SMO 2187/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA IGF1R 962/4885KIF11 2508/4885SMO 2697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.